•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
Niu Technologies to Report Third Quarter 2026 Financial Results on Nov 16, 2026
Niu Technologies Provides Third Quarter 2026 Sales Volume Update
Niu Technologies: A Disappointing Report Comes With A Silver Lining
Niu Technologies (NIU) Q2 2026 Earnings Call Prepared Remarks Transcript
Niu Technologies Q2 Earnings Call Highlights
Niu Technologies Announces Unaudited Second Quarter 2026 Financial Results
Niu Technologies to Report Second Quarter 2026 Financial Results on August 10, 2026
Niu Technologies Provides Second Quarter 2026 Sales Volume Update
Niu Technologies: Strong Revenue Growth Should Eventually Push It Higher
Niu Technologies (NIU) Q1 2026 Earnings Call Transcript
Niu Technologies Q1 Earnings Call Highlights
Niu Technologies Announces Unaudited First Quarter 2026 Financial Results
Niu Technologies to Report First Quarter 2026 Financial Results on May 18, 2026
Niu Technologies Files Its Annual Report on Form 20-F
Niu Technologies Provides First Quarter 2026 Sales Volume Update
Niu Technologies: Why The Time Has Come To Be Long
Niu Technologies Sell-off Signals Opportunity Amid Strong Growth Outlook
Niu Technologies (NIU) Q4 2025 Earnings Call Transcript
Niu Technologies Stock Plummets 13% As Global E-Scooter Sales Crash 68%
Already premium?